Healthcare / BiotechnologyWarsaw
$75.50
+0.50 (+0.67%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-32.3M · quality 68.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$478M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-59.6%
↓Gross Margin
67.0%
↑Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+58.3%
FCF CAGR
—
FCF margin
-204.1%
FCF / Net income
0.84x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $15.8M · net income $-38.4M · FCF $-32.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $15.8M | $15.8M | $13.2M | $9.2M | $4.0M |
| Net Income | $-38.4M | $-38.4M | $-70.6M | $-35.9M | $-32.6M |
| EBITDA | $-33.0M | $-33.0M | $-64.8M | $-28.5M | $-24.8M |
| EPS | -8.25 | -8.25 | -15.19 | -8.61 | -789.00 |
| Gross Margin | 67.0% | 67.0% | 52.3% | 77.2% | 81.4% |
| Operating Margin | -246.2% | -246.2% | -553.1% | -440.8% | -820.6% |
| Net Margin | -242.8% | -242.8% | -534.7% | -391.9% | -817.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.09 | 0.09 | 0.05 | 0.07 | 0.07 |
| Current Ratio | 1.60 | 1.60 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-32.3M | $-32.3M | $-55.2M | $-23.8M | $-33.6M |
| Returns | |||||
| ROE | -59.6% | -59.6% | -102.0% | -37.3% | -26.2% |
| Valuation | |||||
| P/B | 5.46 | 5.46 | 6.96 | 7.42 | 6.31 |
| Growth & Yield | |||||
| Revenue Growth | 19.9% | 19.9% | 44.1% | 129.8% | — |
| EPS Growth | 45.7% | 45.7% | -76.4% | 98.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+122.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-15.19 → -8.25
Residual
+122.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.